← Leaderboards
Beverly Tang
Starlight Cardiovascular, Inc.
$6,687,025
Attributed
$6,687,025
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,687,025 · 5
By mechanism
R44$5,246,454 · 2
R43$940,571 · 2
SB1$500,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Device Designs”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Mark Marino · Venturewell$49,647,567
- Hanjoon Ryu$28,519,898
- Kathleen Maletic Neuzil · Emory University$26,789,412
- Craig Reist · Research Triangle Institute$22,725,934
Research focus
Device DesignsPulmonary Artery StructureOperative Surgical ProceduresNewborn InfantFda ApprovedCardiovascular SystemAnimalsDevicesChildhoodDesignCommercializationProceduresInnovationSafetyVerification And ValidationMedical DeviceDevice Or Instrument DevelopmentCathetersMechanicsSmall Business Innovation Research GrantNeonateChronicMinimally InvasiveAdult
Grant awards (9)
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$999,918
R44 · FY2025 · HL · contact PI
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME$999,901
R44 · FY2025 · HL · contact PI
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME$999,969
R44 · FY2024 · HL · contact PI
Commercialization Readiness for Ductus Arteriosus Stent to Improve Congenital Heart Defect Mortality$500,000
SB1 · FY2024 · HL · contact PI
Administrative Supplement to Promote Diversity in MedTech Through Development of Pulmonary Flow Restrictors$88,483
R44 · FY2024 · HL · contact PI
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$901,548
R44 · FY2023 · HL · contact PI
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$1,256,635
R44 · FY2022 · HL · contact PI
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME$448,000
R43 · FY2022 · HL · contact PI
DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY$492,571
R43 · FY2021 · HL · contact PI